ConductScience.org, home

Comparison · NCT04410328-ba8e053c

Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality. Trial comparisons, record NCT04410328-ba8e053c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04410328-ba8e053c

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04080.01130.137wilson
Risk in group 20.04080.01130.137wilson
Risk difference, group 1 minus group 20-0.1010.101newcombe hybrid score
Risk ratio, group 1 over group 210.1476.82log
Odds ratio, group 1 over group 210.1357.4log
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: standard of care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Participants Receiving Dipyridamole and Aspirin
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.~Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.~Standard of care: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
249OG000
Group 2Participants Receiving Standard of Care
Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.~Standard of care: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
249OG001

Outcome

Type
SECONDARY
Title
Mortality
Description
All-cause mortality assessed on day 14.
Time frame
14 days
Population

Source ClinicalTrials.gov

Trial

Title
Aggrenox To Treat Acute Covid-19
NCT number
NCT04410328
Phases
PHASE3
Conditions
Covid19
Interventions
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
Lead sponsor
Rutgers, The State University of New Jersey
Results first posted
2025-02-21

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04410328-ba8e053c